| 期刊論文| 1. | Lin, Y. H.、Chen, K. K.、Chiu, J. H.(2011)。Use of Chinese medicine among prostate cancer patients in Taiwan: a retrospective longitudinal cohort study。Int. J. Urol.，18，383-386。   | | 2. | Shih, C. C.、Liao, C. C.、Su, Y. C.、Tsai, C. C.、Lin, J. G.(2012)。Gender differences in traditional Chinese medicine use among adults in Taiwan。PLoS One，7，e32540。 | | 3. | Tindle, H. A.、Davis, R. B.、Phillips, R. S.、Eisenberg, D. M.(2005)。Trends in use of complementary and alternative medicine by US adults: 1997-2002。Alternative Therapies in Health and Medicine，11(1)，42-49。 | | 4. | Myers, G. L.、Miller, W. G.、Coresh, J.、Fleming, J.、Greenberg, N.、Greene, T.、Eckfeldt, J. H.(2006)。Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program。Clinical Chemistry，52(1)，5-18。 | | 5. | Thomas, K. J.、Nicholl, J. P.、Coleman, P.(2001)。Use and expenditure on complementary medicine in England: a population based survey。Complement. Ther. Med.，9，2-11。 | | 6. | Eisenberg, D. M.、Davis, R. B.、Ettner, S. L.、Appel, S. M. S.、Wilkey, S.、Van Rompay, M.、Kessler, R. C.(1998)。Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey。Journal of American Medical Association，280(18)，1569-1575。 | | 7. | Hwang, S. J.、Lin, M. Y.、Chen, H. C.、Hwang, S. C.、Yang, W. C.、Hsu, C. C.、Chiu, H. C.、Mau, L. W.(2008)。Increased risk of mortality in the elderly population with late-stage chronic kidney disease: a cohort study in Taiwan。Nephrol. Dial. Transplant.，23，3192-3198。 | | 8. | Wen, C. P.、Cheng, T. Y.、Tsai, M. K.、Chang, Y. C.、Chan, H. T.、Tsai, S. P.、Chiang, P. H.、Hsu, C. C.、Sung, P. K.、Hsu, Y. H.、Wen, S. F.(2008)。All-cause mortality attributable to chronic kidney disease: a prospective cohort study based。Lancet，371，2173-2182。 | | 9. | El Nahas, A. M.、Bello, A. K.(2005)。Chronic kidney disease: the global challenge。Lancet，365，331-340。 | | 10. | Chang, H.、Kwon, Y. D.、Yoon, S. S.(2011)。Use of acupuncture therapy as a supplement to conventional medical treatments for acute ischaemic stroke patients in an academic medical centre in Korea。Complement. Ther. Med.，19，256-263。 | | 11. | Chen, F. P.、Chen, T. J.、Kung, Y. Y.、Chen, Y. C.、Chou, L. F.、Chen, F. J.、Hwang, S. J.(2007)。Use frequency of traditional Chinese medicine in Taiwan。BMC Health Serv. Res.，7，26。 | | 12. | Al-Windi, A.(2004)。Determinants of complementary alternative medicine (CAM) use。Complement. Ther. Med.，12，99-111。 | | 13. | Park, H. L.、Lee, H. S.、Shin, B. C.、Liu, J. P.、Shang, Q.、Yamashita, H.、Lim, B.(2012)。Traditional medicine in china, Korea, and Japan: a brief introduction and comparison。Evidence-Based Complementary and Alternative Medicine，2012，1-9。 | | 14. | Hsieh, C. F.、Huang, S. L.、Chen, C. L.、Chen, W. T.、Chang, H. C.、Wu, M. L.、Yang, C. C.(2012)。Increased risk of chronic kidney disease among users of non-prescribed Chinese herbal medicine in Taiwan。Prev. Med.，55，155-159。 | | 15. | Wang, Y. J.、He, L. Q.、Sun, W.、Lu, Y.、Wang, X. Q.、Zhang, P. Q.、Wei, L. B.、Cao, S. L.、Yang, N. Z.、Ma, H. Z.、Gao, J.、Li, P.、Tao, X. J.、Yuan, F. H.、Li, J.、Yao, C.、Liu, X.(2012)。Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial。J. Ethnopharmacol.，139，757-764。 | | 16. | Chen, F. P.、Kung, Y. Y.、Chen, T. J.、Hwang, S. J.(2006)。Demographics and patterns of acupuncture use in the Chinese population: the Taiwan experience。Journal of Alternative and Complementary Medicine，12(4)，379-387。 | | 17. | Mehta, D. H.、Phillips, R. S.、Davis, R. B.、McCarthy, E. P.(2007)。Use of complementary and alternative therapies by Asian Americans. Results from the National Health Interview Survey。J. Gen. Intern. Med.，22，762-767。 | | 18. | Lai, D.、Chappell, N.(2007)。Use of Traditional Chinese Medicine by older Chinese immigrants in Canada。Fam. Pract.，24，56-64。 | | 19. | Levey, A. S.、Coresh, J.(2012)。Chronic kidney disease。Lancet，379，165-180。 | | 20. | National Kidney Foundation(2002)。K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification。Am. J. Kidney Dis.，39，S1-S266。 | | 21. | Liao, Y. H.、Lin, C. C.、Li, T. C.、Lin, J. G.(2012)。Utilization pattern of traditional Chinese medicine for liver cancer patients in Taiwan。BMC Complement. Altern. Med.，12，146。 | | 22. | Lin, Y. H.、Chiu, J. H.(2011)。Use of Chinese medicine by women with breast cancer: a nationwide cross-sectional study in Taiwan。Complement. Ther. Med.，19，137-143。 | | 23. | Shih, C. C.、Lin, J. G.、Liao, C. C.、Su, Y. C.(2009)。The utilization of traditional Chinese medicine and associated factors in Taiwan in 2002。Chin. Med. J. (Engl.)，122，1544-1548。 | | 24. | Chang, Y. P.、Huang, S. K.、Tao, P.、Chien, C. W.(2012)。A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy。BMC Nephrol.，13，96。 | | 25. | Chang, F. Y.、Lu, C. L.(2009)。Treatment of irritable bowel syndrome using complementary and alternative medicine。J. Chin. Med. Assoc.，72，294-300。 | | 26. | Liu, J. P.、Yang, M.、Liu, Y. X.、Wei, M.、Grimsgaard, S.(2006)。Herbal medicines for treatment of irritable bowel syndrome。Cochrane Database Syst. Rev.，25(1)，CD004116。 | | 27. | Luo, J. C.、Leu, H. B.、Hou, M. C.(2013)。Nonpeptic ulcer, nonvariceal gastrointestinal bleeding in hemodialysis patients。Am. J. Med.，126(3)，(264)e225-(264)e232。 | | 28. | Chen, H. Y.、Lin, Y. H.、Wu, J. C.、Chen, Y. C.、Thien, P. F.、Chen, T. J.、Lo, S. S.(2012)。Characteristics of pediatric traditional Chinese medicine users in Taiwan: a nationwide cohort study。Pediatrics，129，e1485-e1492。 | | 29. | 曲宏達、佟麗、沈劍剛、陳育堯(2002)。補陽還五湯對體外培養的大鼠皮層神經元缺氧凋亡的影響。第一軍醫大學學報，22，35-38。 延伸查詢 | | 30. | 趙雅寧、吳曉光、李建民、陳長香、饒穎臻、李淑杏(2010)。中藥補陽還五湯對沙鼠腦缺血再灌注損傷及微循環障礙的治療作用。四川大學學報（醫學版），41，53-56。 延伸查詢 | | 31. | Hedayati, S. S.、Finkelstein, F. O.(2009)。Epidemiology, diagnosis, and management of depression inpatients with CKD。Am. J. Kidney Dis.，54，741-752。 | | 32. | Nagler, E. V.、Webster, A. C.、Vanholder, R.、Zoccali, C.(2012)。Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP)。Nephrol. Dial. Transplant.，27，3736-3745。 | | 33. | Terauchi, M.、Hiramitsu, S.、Akiyoshi, M.(2011)。Effects of three Kampo formulae: Tokishakuyakusan (TJ-23), Kamishoyosan (TJ-24), and Keishibukuryogan (TJ-25) on Japanese peri- and postmenopausal women with sleep disturbances。Arch. Gynecol. Obstet.，284，913-921。 | | 34. | Zhang, J.、Xie, X.、Li, C.、Fu, P.(2009)。Systematic review of the renal protective effect of Astragalus membranaceus (root) on diabetic nephropathy in animal models。J. Ethnopharmacol.，126，189-196。 | | 35. | Wang, H.、Li, J.、Yu, L.、Zhao, Y.、Ding, W.(2004)。Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis。Life Sci.，74，1645-1658。 | | 36. | Scheid, Volker(2007)。Traditional Chinese medicine: what are we investigating? The case of menopause。Complementary therapies in medicine，15(1)，54-68。 | | 37. | Li, M.、Wang, W.、Xue, J.、Gu, Y.、Lin, S.(2011)。Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy。J. Ethnopharmacol.，133，412-419。 | | 38. | You, H.、Lu, Y.、Gui, D.、Peng, A.、Chen, J.、Gu, Y.(2011)。Aqueous extract of Astragali Radix ameliorates proteinuria in adriamycin nephropathy rats through inhibition of oxidative stress and endothelial nitric oxide synthase。J. Ethnopharmacol.，134，176-182。 | | 39. | 廖春來、佟麗、陳育堯(2004)。補陽還五湯對腦缺血大鼠nNOS免疫陽性神經元的影響。第一軍醫大學學報，24，864-868。 延伸查詢 | | 40. | 劉瑜、林蓉、張慧、張繼業、紀巧麗、楊銀京(2009)。補陽還五湯對異丙腎上腺素誘導大鼠心肌缺血的保護作用。中藥材，32，380-383。 延伸查詢 | | 41. | 陳潔、曾耀英、曾慧蘭、陳孝銀、蘇澤軒、劉嘉雯、王喬峰、李偉、吳文燕(2009)。補陽還五湯預先乾預對大鼠腦死亡後腎臟炎症細胞因子表達的影響。中藥材，32，1855-1860。 延伸查詢 | | 42. | Lai, M. N.、Wang, S. M.、Chen, P. C.、Chen, Y. Y.、Wang, J. D.(2010)。Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk。J. Natl. Cancer Inst.，102，179-186。 | 圖書| 1. | USRDS(2012)。Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States。Bethesda, MD：National Institutes of Health。 | |
| |